In a significant policy shift, NHS England announced that children in the UK will no longer be prescribed puberty blockers at gender identity clinics. This decision, which has received government approval, confines the use of puberty blockers to clinical research trials. The move comes after an independent review and public consultation on gender identity services for under-18s, driven by a notable increase in referrals to the Gender Identity Development Service (Gids) operated by the Tavistock and Portman NHS Foundation Trust.

This policy change occurs against the backdrop of mounting referrals and evolving approaches to treating gender dysphoria in young people. With fewer than 100 young individuals currently receiving puberty blockers, the treatment will continue for them but under specialist supervision at Leeds and University College London Hospitals. Concurrently, the Tavistock clinic’s closure is set to usher in new NHS services in London and Liverpool, which aim for a comprehensive care approach involving a team of clinical experts from various disciplines.

Health Minister Maria Caulfield expressed support for the decision, emphasising its foundation on evidence-based care and prioritising the well-being of children. The government’s endorsement, including from former Prime Minister Liz Truss, points towards a legislative reinforcement of this policy shift.

The establishment of new regional specialist centres is underway, with a vision to enhance support for transgender youth, amid a backdrop of a substantial waiting list for gender identity services. This restructured approach aims not only to provide immediate care but also to contribute to the ongoing evidence base regarding the use of puberty blockers in treating gender dysphoria in children, with a comprehensive study expected to conclude by December 2024.